News | March 21, 2022
Lonza signs manufacturing agreement with Oasmia Pharmaceutical
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
First and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder (CDD) in patients two years of age and older
The expansion reiterates BASF’s continued commitment to Asia Pacific and specifically to customers in the medical glove industry
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus
The meeting was co-organized by World Health Organization’s Country Office for India, World Animal Protection India and ReAct Asia Pacific
MTBVAC is a global public-private project that will be a milestone in the field of vaccinology
Subscribe To Our Newsletter & Stay Updated
